Biotechnologies in the Czech Republic: current status, trends and challenges

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26310%2F21%3APU138556" target="_blank" >RIV/00216305:26310/21:PU138556 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/full/10.1080/13102818.2020.1865201" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/13102818.2020.1865201</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/13102818.2020.1865201" target="_blank" >10.1080/13102818.2020.1865201</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Biotechnologies in the Czech Republic: current status, trends and challenges

Popis výsledku v původním jazyce

This review presents an overview of the current status of the biotechnology sector in the Czech Republic (CR), its future trends and main challenges. CR is the country that laid down the principal laws of heredity, introduced the contact lens to the world and successfully developed the compounds on which current anti-AIDS drugs are based. The history of Czech biotechnology is strongly associated with typical local industries such as beer and wine production. Research institutions focus traditionally on the plant and animal biotechnologies. Recently, biotechnology-related achievements have been oriented preferentially towards nanotechnology, pure biotechnology and human healthcare. The public biotech sector includes, above all, EU programmes. Since 2007, there has been a major investment in large EU-funded research infrastructures outside the Prague region to equalize the competitivness in other regions (Brno, Olomouc) and to complement the existing research institutes. The private sector includes some global companies - Teva Pharmaceutical, Sanofi, Lonza Biotec and Gilead Sciences, among others. The local structure consists almost exclusively of small companies and only several middle-sized companies with a quite high orientation on the inland market. Recently, some clusters were established as platforms for exchanging information on the development of science and technology, identifying synergies and possible collaborations to address critical issues covering the full value chain from R&D to production in the fields of Czech biotech. The big chance for CR biotechnology is the technical crossover with biotech and other sciences, as a possible boost of bioinformatics-driven R&D&I due to very strong ICT in CR.

Název v anglickém jazyce

Biotechnologies in the Czech Republic: current status, trends and challenges

Popis výsledku anglicky

This review presents an overview of the current status of the biotechnology sector in the Czech Republic (CR), its future trends and main challenges. CR is the country that laid down the principal laws of heredity, introduced the contact lens to the world and successfully developed the compounds on which current anti-AIDS drugs are based. The history of Czech biotechnology is strongly associated with typical local industries such as beer and wine production. Research institutions focus traditionally on the plant and animal biotechnologies. Recently, biotechnology-related achievements have been oriented preferentially towards nanotechnology, pure biotechnology and human healthcare. The public biotech sector includes, above all, EU programmes. Since 2007, there has been a major investment in large EU-funded research infrastructures outside the Prague region to equalize the competitivness in other regions (Brno, Olomouc) and to complement the existing research institutes. The private sector includes some global companies - Teva Pharmaceutical, Sanofi, Lonza Biotec and Gilead Sciences, among others. The local structure consists almost exclusively of small companies and only several middle-sized companies with a quite high orientation on the inland market. Recently, some clusters were established as platforms for exchanging information on the development of science and technology, identifying synergies and possible collaborations to address critical issues covering the full value chain from R&D to production in the fields of Czech biotech. The big chance for CR biotechnology is the technical crossover with biotech and other sciences, as a possible boost of bioinformatics-driven R&D&I due to very strong ICT in CR.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management

Projekt

<a href="/cs/project/LO1211" target="_blank" >LO1211: Centrum materiálového výzkumu na FCH VUT v Brně - udržitelnost a rozvoj</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT

ISSN

1310-2818

e-ISSN

1314-3530

Svazek periodika

35

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

224-231

Kód UT WoS článku

000603925300001

EID výsledku v databázi Scopus

—